MilliporeSigma will provide its Provantage End-to-End development and manufacturing services to Y-mAbs Therapeutics in support of Y-mAbs’ monoclonal antibody in late stage clinical development. The antibody, targeting refractory leptomeningeal tumor neuroblastoma and diffuse intrinsic pontine glioma, is a potential breakthrough treatment for pediatric patients. Following transfer of Y-mAbs’ lead cell line to MilliporeSigma, services will include scale-up and GMP manufacturing of a...